AMRN logo

AMARIN CORP PLC -ADR

AMRNNASDAQ
πŸ† #3347 by market capEarnings Feb 23 Β· PostUS Equity
$10.57β–Ό $0.69 (βˆ’6.13%)
Market closed Β· at close
πŸ””
Track AMRN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.1%
7dβ–Ό 7.5%
14dβ–Ό 8.5%
30dβ–Ό 10.7%
ytdβ–Ό 24.6%
1yβ–Ό 35.9%
🏦Market Cap
$4.47B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-37.6%
Declining
πŸ“ŠGross Margin
40.9%
Healthy
πŸ’΅FCF Margin
21.3%
Strong
βš–οΈP/S Ratio
1.3x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$10.53 – $11.18
52-Week Range
$11.15 – $17.31
Volume (shares)
177,908
Avg Volume (shares)
β€”
Shares Outstanding
422.5M
Next Earnings
2027-02-23

Fundamentals Snapshot

Annual Revenue
$214M
Last Q Revenue
$40M
P/E Ratio
β€”
P/S Ratio
1.3x
EPS (TTM)
$-0.05
Dividend Yield
β€”
Dilution (1yr)
+1.2%
AMRN logo

AMARIN CORP PLC -ADR

AMRN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$214Mβ–Ό βˆ’6.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
56.6%β–² +58.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$14Mβ–Ό βˆ’84.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$7Mβ–Ό βˆ’121.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.0Mβ–² +1.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$123Mβ–² +$9M YoY
StockOtter Β· stockotter.space

About AMARIN CORP PLC -ADR

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold2
Sell2
Strong Sell2
Ratings as of Nov 2026

Latest News & Updates

The Motley FoolΒ·11d ago

Amarin: 3 Key Takeaways for Long-Term Investors

Amarin reported its first profitable quarter in two years during Q3. European in-market demand for VAZKEPA grew 68% year over year.

GlobeNewsWireΒ·13d ago

Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026

DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted new clinical data

Zacks Investment ResearchΒ·24d ago

Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark

AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.

Seeking AlphaΒ·24d ago

Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript

MarketBeatΒ·25d ago

What Amarin (AMRN) Said on Its Q3 Earnings Call

Amarin NASDAQ: AMRN reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market demand helped offset c

GlobeNewsWireΒ·25d ago

Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income

DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results f